Navigation Links
Placebo Effect May Work in Reverse
Date:2/17/2011

By Steven Reinberg
HealthDay Reporter

WEDNESDAY, Feb. 16 (HealthDay News) -- Everyone's heard of the placebo effect: when you take a sugar pill but believe it is medicine, it tends to work. Now a new study suggests that the opposite may also be true.

In the study, people's pain levels fluctuated greatly with their belief that they either were or were not receiving a powerful painkiller, remifentanil -- even though the dose of the drug did not change throughout the experiment.

Pain levels shot up, in fact, soon after participants were told that the drug had been discontinued, something experts call the "nocebo" effect.

The findings suggest that doctors may need to deal with their patients' beliefs about a treatment, whether positive or negative, experts say.

"Our study provides evidence that the expectation of a drug's effect critically influences its therapeutic efficacy," said lead researcher Dr. Ulrike Bingel, from the department of neurology at the University of Hamburg Medical Center in Germany.

"We found that positive treatment expectancy substantially enhanced -- doubled -- the analgesic benefit of remifentanil. In contrast, negative treatment expectancy completely abolished remifentanil's painkilling effect," she said.

"Intriguingly, this very same pattern was found in the activation of those brain areas that are well known to be involved in the intensity of pain," Bingel added.

The study, which also involved researchers from Oxford University in the U.K., is published in the Feb. 16 issue of Science Translational Medicine.

For the study, Bingel's team gave 22 healthy volunteers the opioid painkiller remifentanil and then tested its effect by changing the patient's expectations of the treatment.

The participants were first placed inside an MRI brain scanner, and an intravenous line used to administer the drug was attached. The researchers then applied heat to each volunteer's leg to the point of causing pain, and set the heat at such a level that each participant initially rated their pain at 70 out of 100. At the same time, they gave the volunteers remifentanil but did not tell them they were doing so.

As would be expected with the powerful drug taking effect, the average level of self-reported pain participants felt declined a bit, falling from 66 points down to 55 on a 100-point scale.

The researchers then told the volunteers that the remifentanil was starting (even though they had already been getting the drug). The result: participants' average pain levels fell dramatically, to 39 points.

To test the "nocebo" effect, Bingel's team then told the volunteers they were stopping the drug and they might start to feel more pain again -- a lie, since they continued to administer the same level of the painkiller.

At this point, the volunteers' self-reported pain levels shot back up to an average of 64 points -- that is, the pain was as great as if they had received no pain relief at all.

In each stage of the experiment, MRI scans showed different brain activity in responses to the volunteer's varied expectations of pain or pain relief, the researchers said. Specifically, in people who were primed to think they were getting the painkiller, areas of the brain were engaged that made it more difficult for pain signals to reach the brain or spinal cord, the researchers said.

Bingel believes that the data "opens a new avenue of research," linking up drugs with patients' personalities and expectations in the context of specific medical conditions.

The findings also have implications for clinical practice, she said. "We believe that the beliefs, expectations and previous experiences with drug treatments should be more systematically assessed and integrated [by doctors] to optimize the overall treatment outcome."

One expert agreed.

Dr. Fatta B. Nahab, an assistant professor of neurology at the University of Miami's Miller School of Medicine, said the study shows that patient expectation can have an impact on outcomes.

"What this teaches doctors is that you have to do a great job of educating patients about their treatments, and also limit false or negative expectations," he said. "If we do that our outcomes would be much better and, I think, patients would be more satisfied with the treatments they are getting."

The findings may also point to ways of harnessing the brain to improve treatments.

"People have talked about bottling the placebo response," Nahab said. "This is our first indication of how we might bottle that placebo response. If we could go into some of these regions and figure out if we could change them, we might be able to enhance the efficacy of any medication or any treatment, and that's really the huge part of this work."

More information

For more information on pain management, visit the U.S. National Library of Medicine.

SOURCES: Ulrike Bingel, M.D., department of neurology, University of Hamburg Medical Center, Germany; Fatta B. Nahab, M.D., assistant professor of neurology, Miller School of Medicine, University of Miami; Feb. 16, 2011, Science Translational Medicine


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Placebos Work -- Even if Patients Are in on the Secret
2. Placebo Pill Gives Boost to Some Womens Sex Drive
3. Placebo successful in treating women with sexual dysfunction
4. Transforaminal steroid injection for lumbar radicular pain proves superior to placebo
5. Quincy Bioscience Announces Encouraging Preliminary Results of Randomized, Double-Blind, Placebo-Controlled Memory Study
6. Calorie labeling has no effect on teenagers or parents food purchases
7. Red wine compound increases anti-tumor effect of rapamycin
8. Dermatitis May Be More Cause Than Effect of Food Allergies
9. Homogeneous tuberculosis treatment ineffective in children, UT Southwestern researchers find
10. Dutasteride not a cost-effective way to prevent prostate cancer in some men
11. New Heart Failure Therapy Proves Most Effective in Women
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
 Placebo Effect May Work in Reverse 
(Date:5/26/2017)... ... May 26, 2017 , ... via seating is ... back 24/7 task chair specifically designed for clinical areas. Genie Copper Mesh is ... partner with Cupron® to provide customers with a game changing chair that is ...
(Date:5/26/2017)... ... ... After raising nearly $30,000 on Kickstarter , about three-times its original campaign ... crowdfunding price on Indiegogo . , “Along with creating an anti-stress gadget to ... fidget toy to the market that was made of superior quality and wouldn’t break ...
(Date:5/26/2017)... Illinois (PRWEB) , ... May 26, 2017 , ... Silver ... The community, which is located on more than four acres of land at 5620 ... independence. , The 103,000 square-foot building includes 125 studio and one-bedroom apartments. Each ...
(Date:5/26/2017)... San Francisco, CA (PRWEB) , ... May 26, 2017 , ... ... San Francisco, is proud to announce a new, informational blog post on insurance options. ... tooth surgery, checking insurance plans may help save time and money. Visiting an in-network ...
(Date:5/26/2017)... ... May 26, 2017 , ... “THE FLINTHILLS FAMILY-Our Journey to the Cross”: the personal journey of ... Cross” is the creation of published authors, Bob and Margaret Massey. Bob Massey is ... is "panther quick and leather tough." His love for others is apparent in all ...
Breaking Medicine News(10 mins):
(Date:5/23/2017)... , May 23, 2017  Leaf Healthcare, ... innovative medical devices for pressure ulcer prevention, will ... American Association of Critical Care Nurses, National Teaching ... 22-25. The Leaf Patient Monitoring System ... for the hospital environment.  The system seamlessly tracks ...
(Date:5/18/2017)... 18, 2017  Two Bayer U.S. Pharmaceutical leaders received ... its recent 28 th Woman of the ... showcases HBA,s longstanding mission of furthering the advancement and ... Cindy Powell-Steffen , senior director of brand ... and Libby Howe , a regional business manager ...
(Date:5/15/2017)... Enterin Inc., a privately-held CNS pharmaceutical company based in ... Parkinson,s disease (PD), has enrolled the first patient in the ... multicenter study involving patients with PD and taking place at ... 9-to-12-month period. The first stage is open label and involves ... include Denver , Boca Raton ...
Breaking Medicine Technology: